Ocular Therapeutix
OCUL
116 hedge funds and large institutions have $111M invested in Ocular Therapeutix in 2022 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 40 increasing their positions, 42 reducing their positions, and 26 closing their positions.
12% more call options, than puts
Call options by funds: $788K | Put options by funds: $703K
5% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 42
4.12% less ownership
Funds ownership: 55.57% → 51.45% (-4.1%)
11% less funds holding
Funds holding: 130 → 116 (-14)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
38% less capital invested
Capital invested by funds: $178M → $111M (-$66.9M)
54% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$1.84M |
| 2 |
Barclays
London,
United Kingdom
|
+$1.04M |
| 3 |
Renaissance Technologies
New York
|
+$924K |
| 4 |
Morgan Stanley
New York
|
+$793K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$611K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.65M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$2.21M |
| 3 |
ACM
Altium Capital Management
New York
|
-$2.15M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$1.79M |
| 5 |
DAM
Deltec Asset Management
New York
|
-$1.56M |
OCUL Hedge Fund Activity: Q4 2022 in Review
116 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q4 2022, worth a combined $111M — down 38% from $178M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of OCUL and 12 opened new positions — a net loss of 14 holders — while 42 trimmed existing stakes and 40 added.
The largest buyer was Citadel Advisors, adding an estimated $1.84M. The largest seller was Federated Hermes, cutting an estimated $2.65M.
- 116 institutional investors held Ocular Therapeutix (OCUL) as of Q4 2022, down from 130 in Q3 2022.
- Funds reported $111M of Ocular Therapeutix stock for Q4 2022, down 38% quarter-over-quarter.
- 12 funds opened new Ocular Therapeutix positions in Q4 2022 and 26 closed out, a net change of -14 holders.
- The largest Ocular Therapeutix buyer in Q4 2022 was Citadel Advisors, an estimated $1.84M added.
- The largest Ocular Therapeutix seller in Q4 2022 was Federated Hermes, an estimated $2.65M sold.
Based on aggregated 13F filings for Q4 2022.